Fig 1.
Chikungunya vaccine development to introduction pathway.
Schematic showing the vaccine development process for the chikungunya vaccine alongside stages of licensure and evidence-based recommendations for policy making decisions. WHO–World Health Organization; MoH–Ministry of Health, NRA—National Regulatory Agencies, SAGE–Strategic Advisory Group of Experts, EPI–Expanded Program for Immunization, NITAG–National Immunization Technical Advisory Group, PQ- Pre-qualification.
Fig 2.
Evidence-to-Recommendation criteria for chikungunya vaccine introduction.
The Evidence-to-Recommendation criteria for chikungunya vaccine introduction is based on the World Health Organization’s Guidance on an adapted Evidence-to-Recommendation Process for National Immunization Technical Advisory Groups.
Table 1.
Participant characteristics by geographical region and type of stakeholder.
Table 2.
Themes and challenges presented by stakeholders in different organisation tiers and by geographical regions.
Table 3.
Mapping stakeholder perspectives with Evidence-to-Recommendation criteria.
Stakeholder perspectives were aligned with Evidence-to-Recommendation criteria to highlight existing gaps in knowledge. Cells in the table without data mean these topics were not discussed by any of the stakeholders.